Tg Therapeutics earnings were $461.9M for the trailing 12 months ending Mar 31, 2026, with 1,092.6% growth year over year. The latest TGTX earnings report on Mar 31, 2026 announced Q1 2026 earnings of $19.8M, down 14.2% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, TGTX reported annual earnings of $447.2M, with 1,812.4% growth.
TGTX past earnings growth
How has TGTX's earnings growth performed historically?
What were Tg Therapeutics's earnings last quarter?
Tg Therapeutics (NASDAQ: TGTX) reported Q1 2026 earnings per share (EPS) of $0.14, up 366.67% year over year. Total TGTX earnings for the quarter were $19.78 million. In the same quarter last year, Tg Therapeutics's earnings per share (EPS) was $0.03.
As of the last Tg Therapeutics earnings report, Tg Therapeutics is currently profitable. Tg Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was $461.90 million, a 1,079.81% increase year over year.
What was TGTX's earnings growth in the past year?
As of Tg Therapeutics's earnings date in Q2 2026, Tg Therapeutics's earnings has grown 1,092.59% year over year. This is 1,045.82 percentage points higher than the US Biotechnology industry earnings growth rate of 46.77%. TGTX earnings in the past year totalled $461.90 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.